Investor Relations

Stocktwits

News

    Events

    No items found

    Webcasts & Presentations

      Reports & Filings

          Date Filing Description Download

            Stock Information

            Stock Quote: NASD

            Price 0.32
            Change -0.00
            Volume 152,206
            % Change -1.41%
            Intraday High 0.32
            52 Week High 5.40
            Intraday Low 0.32
            52 Week Low 0.29
            Today's Open 0.32
            Previous Close 0.32
            Dec 10, 2018 02:21 PM Pricing delayed 20 minutes

            *On May 10, 2016 the Company effected a 1:15 reverse stock split.

            Analyst Firm
            Jason Kolbert H.C. Wainwright
            Yale Jen Laidlaw & Company
            Jason McCarthy Maxim Group
            Stephen G. Brozak WBB Securities, LLC

            Cytori Therapeutics is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Cytori Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Cytori Therapeutics or its management. Cytori Therapeutics does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

            Computershare Investor Services

            Mailing Addresses
            Shareholder correspondence should be mailed to:
            Computershare
            P.O. BOX 30170
            College Station, TX 77842-3170

            Overnight correspondence should be sent to:
            Computershare
            211 Quality Circle, Suite 210
            College Station, TX 77845

            Shareholder Website
            www.computershare.com/investor

            Shareholder Online Inquiries
            www-us.computershare.com/investor/Contact

            Management Team

            Marc H. Hedrick, M.D. , , , President/CEO

            Dr. Marc H. Hedrick was appointed President in May 2004 and CEO in 2014. Dr. Hedrick joined Cytori Therapeutics as Chief Scientific Officer, Medical Director and Director in October 2002. Previously, Dr. Hedrick co-founded, and served as President and Chief Executive Officer of StemSource, Inc., a company specializing in stem cell research and development. Dr. Hedrick, a plastic surgeon by training, is a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). From 1998 until 2005, Dr. Hedrick directed the Laboratory of Regenerative Bioengineering and Repair for the Department of Surgery at UCLA. Dr. Hedrick obtained his M.D. from the University of Texas Southwestern Medical School, Dallas and an M.B.A from UCLA in 2005.

            Tiago M. Girão , , , Vice President of Finance and Chief Financial Officer

            Mr. Tiago Girão was appointed Vice President of Finance and Chief Financial Officer (CFO) in September 2014. Mr. Girão joins Cytori Therapeutics from NuVasive, Inc. where he recently served as International Controller. Prior to his International Controller role, he served as Director, Financial Reporting, where he managed a team responsible for all corporate technical accounting and SEC related matters. Prior to joining NuVasive, Mr. Girão served as Senior Manager, Assurance at KPMG, Cytori’s independent audit firm and was responsible for Cytori’s account for six years. Prior to joining KPMG, Mr. Girão was a senior accountant for Ernst & Young in Brazil. Mr. Girão is a certified public accountant with 14 years experience in the accounting, finance and reporting for U.S. public companies and substantial experience in global finance and operations.

            John K. Fraser, PhD , , , Chief Scientist

            Dr. John Fraser is the Chief Scientist at Cytori Therapeutics Inc. Prior to joining Cytori, Dr. Fraser had a 12 year career in the Department of Medicine at UCLA. Before joining Cytori, he was the Director and Principal Investigator of the UCLA Umbilical Cord Blood Bank, a NIH-funded allogeneic cord blood stem cell bank. Dr Fraser has a PhD from the University of Otago in New Zealand and a Bachelor of Science degree (Biochemistry and Physiology) from Victoria University of Wellington. He has published more than 40 peer-reviewed papers, has 12 patents issued in the USA. During his career has been awarded more than $12 million in research contract and grant funding from the National Institutes of Health.

            Cheri Rice , , , Vice President, Portfolio Management and Development

            Cheri Rice was appointed Vice President, Portfolio Management and Development at Cytori Therapeutics, Inc. in August of 2015. Prior to joining Cytori, she served as Vice President of Disposable Development for Volcano Corporation, a leading developer of intravascular ultrasound diagnostic equipment from June 2008 until May 2015. Prior to Volcano she worked her way up through the ranks at Abbott Vascular, ending her tenure as Manager of Process Development. She brings 27 years of Program Management and Engineering in experience to Cytori. Cheri has her bachelor’s degree in Mechanical Engineering from San Diego State University.

            Russ Havranek , , , Vice President, Global Marketing and Business Development

            Russ Havranek serves as Vice President, Global Marketing and Business Development and joined Cytori in 2014. Mr. Havranek has 20 years of marketing, general management, and product development experience with major life science companies including CareFusion Corporation, Volcano Corporation, Guidant Corporation, and Johnson & Johnson. Mr. Havranek received a M.B.A. in Marketing from the University of California, Berkeley, a M.S. in Bioengineering from Clemson University, and a B.S. in Biomedical Engineering from Northwestern University.

            Board of Directors

            Richard J. Hawkins , , , Chairman

            Richard J. Hawkins joined us as Director in December 2007 and was appointed to serve as Chairman in January 2018. Mr. Hawkins is currently the CEO of Lumos Pharma, Inc., a start-up pharma company. Mr. Hawkins founded LabNow Inc., a diagnostic device company developing rapid, point-of-care, physician office-based diagnostic testing systems, and served Chairman and CEO from 2004 until October 2009. Mr. Hawkins previously founded and guided the growth of Pharmaco, a clinical drug development services company where he served as Chairman, President, and Chief Executive Officer. He is a founder of id2, a pharmaceutical and biotechnology research management company, Sensus Drug Development Corp., a biotechnology company that was sold to Pfizer, and Covance Biotechnology Services, and served as Chairman of the Board for LoopOne, Inc., a shipping and logistics software company. Mr. Hawkins holds a B.S. in biology from Ohio University.

            Marc H. Hedrick , , , President/CEO

            Dr. Marc H. Hedrick was appointed President in May 2004 and as CEO in 2014. Dr. Hedrick joined Cytori Therapeutics as Chief Scientific Officer, Medical Director and Director in October 2002. Previously, Dr. Hedrick co-founded, and served as President and Chief Executive Officer of StemSource, Inc., a company specializing in stem cell research and development. Dr. Hedrick, a plastic surgeon by training, is a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). From 1998 until 2005, Dr. Hedrick directed the Laboratory of Regenerative Bioengineering and Repair for the Department of Surgery at UCLA. Dr. Hedrick obtained his M.D. from the University of Texas Southwestern Medical School, Dallas and an M.B.A from UCLA in 2005.

            Gregg A Lapointe , , , Director

            Gregg A. Lapointe has served on our Board since March 2017. Mr. Lapointe is currently the Chief Executive Officer of Cerium Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company. From April 2008 to March 2012, Mr. Lapointe served as Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc., a pharmaceutical company focused on rare disorders and the U.S. wholly-owned subsidiary of Sigma-Tau Finanziaria S.pA. He served as Chief Operating Officer of Sigma-Tau Pharmaceuticals, Inc. from November 2003 to March 2008. Mr. Lapointe also serves on the boards of SciClone Pharmaceuticals, Inc., a publicly-held specialty pharmaceutical company (since March 2009), Soligenix, Inc., a publicly-held biopharmaceutical company (since March 2009), Immunocellular Therapeutics, Ltd., a publicly held pharmaceutical company (since September 2015) and S1Biopharma, Inc. a privately held biopharmaceutical company. Mr. Lapointe previously served as a director of Raptor Pharmaceuticals Corp. from December 2014 until its acquisition by Horizon Pharma plc in October 2016. Mr. Lapointe is a Certified Public Accountant in the United States. He holds a Bachelor of Commerce degree from Concordia University of Montreal, a Graduate Diploma in Public Accountancy from McGill University of Montreal and an M.B.A. from Duke University. Mr. Lapointe’s qualifications to sit on our Board include his substantial experience in finance, management and specialty drug commercialization, including operational experience as the CEO of a pharmaceutical development and sales organization.

            Gary A. Lyons , , , Director

            Gary A. Lyons joined Cytori as a Director in October 2013. Mr. Lyons has served on the Board of Directors of Neurocrine Biosciences since 1993 and as the President and Chief Executive Officer of Neurocrine from 1993 through January 2008. Prior to joining Neurocrine Biosciences, Mr. Lyons held a number of senior management positions at Genentech, Inc., including Vice President of Business Development and Vice President of Sales. Mr. Lyons currently serves on the Boards of Directors for Rigel Pharmaceuticals, Inc., Vical Incorporated, and KaloBios Pharmaceuticals, Inc. Mr. Lyons was previously a director of PDL BioPharma, Inc., Poniard Pharmaceuticals, Inc., Neurogesx and Facet Biotech Corporation. Mr. Lyons holds a B.S. in marine biology from the University of New Hampshire and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management.

            Ronald A. Martell , , , Director

            Ronald A. Martell joined our Board in December 2016. Mr. Martell has more than 25 years’ experience building and managing unique businesses in the biotech industry, and most recently served as Executive Chairman of KaloBios and as Chief Executive Officer at Sevion Therapeutics, prior to which he held similar roles at NeurogesX and at Poniard Pharmaceuticals. Earlier in his career Mr. Martell served as Senior Vice President of Commercial Operations at ImClone Systems, where he built ImClone Systems’ worldwide commercial operations and field sales force to market and commercialize Erbitux® with partners Bristol-Myers Squibb and Merck KGaA. Prior to joining ImClone Systems, Mr. Martell worked for more than 10 years at Genentech in a variety of leadership positions, the last of which was Group Manager, Oncology. At Genentech, he was responsible for building the company’s oncology franchise including the launch of Herceptin® for metastatic HER-2 positive breast cancer and Rituxan® for non-Hodgkin’s lymphoma.

            Board Committees

            Charters

            Download
            Audit Commitee Charter 194 KB
            Compensation Committee Charter 200 KB
            Governance & Nominating Charter 184 KB
             = Chair    = Member
            Committee Member
            Richard J. Hawkins
            Gregg A. Lapointe
            Audit
            Compensation
            Gary A. Lyons
            Compensation
            Governance & Nominating
            Ronald Martell
            Audit
            Governance & Nominating
            Committee Member Audit Compensation Governance & Nominating
            Richard J. Hawkins


            Gregg A. Lapointe

            Gary A. Lyons

            Ronald Martell
             = Chair    = Member

            Corporate Governance  Materials

            Download
            Code of Business Conduct & Ethics 534 KB
            Lighthouse Services 570 KB
            Conflict Minerals Policy 146 KB
            Conflict Minerals Report 287 KB

            Meetings & Proxy Materials

            Annual Stockholder Meeting
            Date: May 18, 2018
            Time: 9 AM PST
            Location: Cytori Therapeutics, Inc.
            3020 Callan Rd. San Diego, CA 92121

            Record Date: March 21, 2018

            Electronic Proxy & Stockholder Material
            Cytori Therapeutics is pleased to offer stockholders the option of electronic delivery of its proxy statements and annual 10-K for the 2016 annual meeting. Electronic delivery benefits Cytori and its stockholders through the reduction of printing costs and paper usage, thereby benefiting the environment. We encourage you to enroll.

            Download
            2017 Annual Report & Proxy Statement 6.32 MB

            Information Request

            Email Address:*  
            First Name:*  
            Last Name:*  
            Company:
            Address1:
            Address2:
            Postal Code:
            Country:
             
            Enter the code shown above.
             

            Investor Relations Contact

            Cytori Therapeutics, Inc.
            Tiago Girao
            Chief Financial Officer
            Phone: 2041-858-458-0900
            Email: ir@cytori.com

            PCG Advisory
            Vivian Cervantes
            Investor Relations
            Phone: (212) 554-5482
            Email: vivian@pcgadvisory.com

            RSS Feeds

            What is RSS?

            Really Simple Syndication (RSS) is a technology that allows you to receive updated news from preferred websites, which are sent directly to the user's news reader. This includes the headlines, summaries and links to the full article on the website.

            What are the benefits of using RSS?

            RSS is an easy way to be notified about updated content on a website. Instead of having to visit a particular website, RSS will automatically send a notification when the subscribed section has been updated.

            How can I sign up to RSS feeds?

            To subscribe to an RSS feed, select the location of the website of interest and click the small orange button (these buttons usually only exist on the Events, Press Releases, and Presentations) to subscribe to the RSS feed. Next, simply follow the instructions for the particular RSS reader being used.

            Email Alerts

            Email Address *
            Mailing Lists *





             
            Enter the code shown above.

            Unsubscribe

            Email Address:  *